NCT06741800

Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis

Microbial Characterization in Patients With Allergic Rhinitis Before and After Sublingual Immunotherapy Tablets

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The incidence of allergic rhinitis (AR) in Chinese adults was reported to be as high as 24.1% and 16.8% in children. The current symptomatic treatment has the disadvantage of poor efficacy and cannot change the natural course of the disease. Allergen immunotherapy (AIT) is the only causative treatment approved by the WHO, bringing a new option to patients with allergic diseases. The quality of allergen preparations is critical to the diagnosis and treatment of the disease, emphasizing the need for standardized preparations, and AIT treatment in the early stages of the disease may change the long-term progression of the disease. Recent studies have reported that the microbiome of patients with different efficacy of desensitization therapy is different and may be correlated with the clinical symptoms of patients, but no prospective studies have been reported.

Conditions

• Rhinitis, Allergic

Interventions

Type	Name	Description
DRUG	ACARIZAX®️	ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.

Timeline

• Start date: 2024-12-20
• Primary completion: 2028-07-01
• Completion: 2032-07-01
• First posted: 2024-12-19
• Last updated: 2024-12-19

Locations

1 site across 1 country: China